These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 19263321)

  • 1. [Neonatal diabetes mellitus: treatment with sulfonylurea in a preterm born infant].
    Holl RW
    Klin Padiatr; 2009; 221(2):52-3. PubMed ID: 19263321
    [No Abstract]   [Full Text] [Related]  

  • 2. [Neonatal diabetes mellitus: treatment with sulfonylurea in a preterm born infant].
    Wendelin G; Haim M; Reiterer F; Borkenstein M; Müller W
    Klin Padiatr; 2009; 221(2):100. PubMed ID: 19263329
    [No Abstract]   [Full Text] [Related]  

  • 3. Sulfonylurea-responsive diabetes in childhood.
    Landau Z; Wainstein J; Hanukoglu A; Tuval M; Lavie J; Glaser B
    J Pediatr; 2007 May; 150(5):553-5. PubMed ID: 17452235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary sulphonylurea therapy in a newborn with transient neonatal diabetes attributable to a paternal uniparental disomy 6q24 (UPD6).
    Neumann U; Bührer C; Blankenstein O; Kühnen P; Raile K
    Diabetes Obes Metab; 2018 Feb; 20(2):474-475. PubMed ID: 28817249
    [No Abstract]   [Full Text] [Related]  

  • 5. Outpatient transition of an infant with permanent neonatal diabetes due to a KCNJ11 activating mutation from subcutaneous insulin to oral glyburide.
    Bremer AA; Ranadive S; Lustig RH
    Pediatr Diabetes; 2008 Jun; 9(3 Pt 1):236-9. PubMed ID: 18221420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An oral sulfonylurea in the treatment of transient neonatal diabetes mellitus.
    Loomba-Albrecht LA; Glaser NS; Styne DM; Bremer AA
    Clin Ther; 2009 Apr; 31(4):816-20. PubMed ID: 19446154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glibenclamide treatment in relapsed transient neonatal diabetes as a result of a KCNJ11 activating mutation (N48D).
    Martín-Frías M; Colino E; Pérez de Nanclares G; Alonso M; Ros P; Barrio R
    Diabet Med; 2009 May; 26(5):567-9. PubMed ID: 19646201
    [No Abstract]   [Full Text] [Related]  

  • 8. Transition from insulin to glyburide in a 4-month-old girl with neonatal diabetes mellitus caused by a mutation in KCNJ11.
    Chan YM; Laffel LM
    Pediatr Diabetes; 2007 Aug; 8(4):235-8. PubMed ID: 17659066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transient neonatal diabetes mellitus in extremely preterm infant.
    Nishimaki S; Yukawa T; Makita Y; Honda H; Kikuchi N; Minamisawa S; Yokota S
    Arch Dis Child Fetal Neonatal Ed; 2008 May; 93(3):F240-1. PubMed ID: 18192332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Glibenclamide: its therapeutic effect in diabetes mellitus].
    Concha E; Veit O
    Rev Med Chil; 1971 Mar; 99(3):217-9. PubMed ID: 4999506
    [No Abstract]   [Full Text] [Related]  

  • 11. Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11.
    Mlynarski W; Tarasov AI; Gach A; Girard CA; Pietrzak I; Zubcevic L; Kusmierek J; Klupa T; Malecki MT; Ashcroft FM
    Nat Clin Pract Neurol; 2007 Nov; 3(11):640-5. PubMed ID: 17982434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Permanent neonatal diabetes mellitus in monozygotic twins achieving low-dose sulfonylurea therapy.
    Hicks KA; Kushner JA; Heptulla R; Ham JN
    J Pediatr Endocrinol Metab; 2014 Jan; 27(1-2):135-8. PubMed ID: 23959658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transfer to sulphonylurea therapy in adult subjects with permanent neonatal diabetes due to KCNJ11-activating [corrected] mutations: evidence for improvement in insulin sensitivity.
    Malecki MT; Skupien J; Klupa T; Wanic K; Mlynarski W; Gach A; Solecka I; Sieradzki J
    Diabetes Care; 2007 Jan; 30(1):147-9. PubMed ID: 17192350
    [No Abstract]   [Full Text] [Related]  

  • 14. Glibenclamide for neonatal diabetes.
    Kochar IP; Jindal R
    Indian Pediatr; 2013 Apr; 50(4):428-9. PubMed ID: 23665609
    [No Abstract]   [Full Text] [Related]  

  • 15. Remission of severe neonatal diabetes with very early sulfonylurea treatment.
    Marshall BA; Green RP; Wambach J; White NH; Remedi MS; Nichols CG
    Diabetes Care; 2015 Mar; 38(3):e38-9. PubMed ID: 25715421
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment with glibenclamide in maturity-onset diabetes mellitus.
    Persson I; Madsen SN
    Geriatrics; 1971 May; 26(5):182-3 passim. PubMed ID: 4997365
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical testing of a sulfonylurea preparation (glibenclamide)].
    Sigroth K; Steen B; Svanborg A
    Lakartidningen; 1969 Nov; 66(45):4647-50. PubMed ID: 4996889
    [No Abstract]   [Full Text] [Related]  

  • 18. Neonatal Diabetes Mellitus: An Update on Diagnosis and Management.
    Lemelman MB; Letourneau L; Greeley SAW
    Clin Perinatol; 2018 Mar; 45(1):41-59. PubMed ID: 29406006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetes treatment in two pregnant women with permanent neonatal diabetes mellitus due to a KCNJ11 mutation.
    Stanik J; Barak L; Dankovcikova A; Valkovicova T; Skopkova M; Gasperikova D
    Diabet Med; 2020 Nov; 37(11):1956-1958. PubMed ID: 32634858
    [No Abstract]   [Full Text] [Related]  

  • 20. No beta cell desensitisation after a median of 68 months on glibenclamide therapy in patients with KCNJ11-associated permanent neonatal diabetes.
    Iafusco D; Bizzarri C; Cadario F; Pesavento R; Tonini G; Tumini S; Cauvin V; Colombo C; Bonfanti R; Barbetti F
    Diabetologia; 2011 Oct; 54(10):2736-8. PubMed ID: 21822789
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.